Investor Relations

English Français

Latest News

Sep 25, 2025

Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors

View Press Release

Aug 12, 2025

Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection

Aug 5, 2025

Medexus Schedules First Fiscal Quarter 2026 Conference Call

View All News

Treosulfan Pivotal Study Results with Dr. Filippo Milano, MD

Q1 2026

Quarter Ended Jun 30, 2025

Earnings Release

PDF HTML

Audio

Earnings Webcast

Management Discussion & Analysis

PDF

Financial Statements

PDF

Company Overview

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and allergy, dermatology, and rheumatology.

The leading prescription products are GRAFAPEX and Trecondyv, indicated in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT); IXINITY, for control & prevention of bleeding episodes & for perioperative management of patients with Hemophilia B; Rasuvo and Metoject, unique formulations of methotrexate (auto-injector and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases and Rupall, an innovative allergy medication with a unique mode of action.

Investor Contact Information

Company

Medexus Pharmaceuticals, Inc.
10 King Street East, Suite 600
Toronto, ON M5C 1C3
Canada
T: 877-422-5242